Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191,114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z. Guo Y, et al. Among authors: liu j, liu y, liu x, liu l, liu g. J Med Chem. 2019 Sep 12;62(17):7923-7940. doi: 10.1021/acs.jmedchem.9b00687. Epub 2019 Aug 19. J Med Chem. 2019. PMID: 31381333
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z, Yuan X, Du R, Cheung SH, Zhang G, Wei J, Zhao Y, Feng Y, Peng H, Zhang Y, Du Y, Hu X, Gong W, Liu Y, Gao Y, Liu Y, Hao R, Li S, Wang S, Ji J, Zhang L, Li S, Sutton D, Wei M, Zhou C, Wang L, Luo L. Tang Z, et al. Among authors: liu y. Mol Cancer Ther. 2015 Oct;14(10):2187-97. doi: 10.1158/1535-7163.MCT-15-0262. Epub 2015 Jul 24. Mol Cancer Ther. 2015. PMID: 26208524
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I. Flinsenberg TWH, et al. Among authors: liu y. Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020. Haematologica. 2020. PMID: 31171645 Free PMC article. No abstract available.
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X, Tang Z, Du R, Yao Z, Cheung SH, Zhang X, Wei J, Zhao Y, Du Y, Liu Y, Hu X, Gong W, Liu Y, Gao Y, Huang Z, Cao Z, Wei M, Zhou C, Wang L, Rosen N, Smith PD, Luo L. Yuan X, et al. Among authors: liu y. Mol Oncol. 2020 Aug;14(8):1833-1849. doi: 10.1002/1878-0261.12698. Epub 2020 May 18. Mol Oncol. 2020. PMID: 32336014 Free PMC article.
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, Wang F, Zhu Y, Zhao Y, Wu Y, Qin Z, Sun X, Ren B, Jiang B, Jin W, Shen Z, Tang Z, Song X, Wang L, Liu X, Zhou C, Jiang B. Xiong Y, et al. Among authors: liu y, liu x. Neoplasia. 2020 Sep;22(9):431-440. doi: 10.1016/j.neo.2020.06.009. Epub 2020 Jul 8. Neoplasia. 2020. PMID: 32652442 Free PMC article.
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, Luo L, Kuang X, Qiu M, Lv L, Xu H, Qi R, Yan H, Xu D, Wang Z, Huo CX, Zhu Y, Zhao Y, Wu Y, Qin Z, Su D, Tang T, Wang F, Sun X, Feng Y, Peng H, Wang X, Gao Y, Liu Y, Gong W, Yu F, Liu X, Wang L, Zhou C. Wang H, et al. Among authors: liu y, liu x. J Med Chem. 2020 Dec 24;63(24):15541-15563. doi: 10.1021/acs.jmedchem.0c01346. Epub 2020 Dec 2. J Med Chem. 2020. PMID: 33264017
Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.
Guo Y, Hu N, Liu Y, Zhang W, Yu D, Shi G, Zhang B, Yin L, Wei M, Yuan X, Luo L, Wang F, Song X, Xin L, Wei Q, Li Y, Guo Y, Chen S, Zhang T, Zhang S, Zhou X, Zhang C, Su D, Liu J, Cheng Z, Zhang J, Xing H, Sun H, Li X, Zhao Y, He M, Wu Y, Guo Y, Sun X, Tian A, Zhou C, Young S, Liu X, Wang L, Wang Z. Guo Y, et al. Among authors: liu j, liu y, liu x. J Med Chem. 2023 Mar 23;66(6):4025-4044. doi: 10.1021/acs.jmedchem.2c01938. Epub 2023 Mar 13. J Med Chem. 2023. PMID: 36912866
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B, Zhang T, Deng M, Jin W, Hong Y, Chen X, Chen X, Wang J, Hou H, Gao Y, Gong W, Wang X, Li H, Zhou X, Feng Y, Zhang B, Jiang B, Lu X, Zhang L, Li Y, Song W, Sun H, Wang Z, Song X, Shen Z, Liu X, Li K, Wang L, Liu Y. Jiang B, et al. Among authors: liu y, liu x. Front Med. 2023 Dec;17(6):1170-1185. doi: 10.1007/s11684-023-0996-8. Epub 2023 Sep 25. Front Med. 2023. PMID: 37747585
Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
Liu J, Li S, Wang Q, Feng Y, Xing H, Yang X, Guo Y, Guo Y, Sun H, Liu X, Yang S, Mei Z, Zhu Y, Cheng Z, Chen S, Xu M, Zhang W, Wan N, Wang J, Ma Y, Zhang S, Luan X, Xu A, Li L, Wang H, Yang X, Hong Y, Xue H, Yuan X, Hu N, Song X, Wang Z, Liu X, Wang L, Liu Y. Liu J, et al. Among authors: liu y, liu x. Blood. 2024 May 2;143(18):1825-1836. doi: 10.1182/blood.2023019706. Blood. 2024. PMID: 38211332 Free PMC article.
191,114 results
You have reached the last available page of results. Please see the User Guide for more information.